A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company developing a portfolio of novel and proprietary molecular glue degraders, or “MGDs”. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins, in effect editing the human proteome. MGDs function by inducing the engagement of an E3 ligase, such as cereblon, with defined structural features on surfaces of target proteins. These target proteins are also referred to as neosubstrates. The E3 ligase then tags the target protein for degradation by adding a molecular mark known as ubiquitin. We believe our MGDs provide significant advantages over existing therapeutic modalities, including other protein degradation approaches.
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 182M | 76M | 0 |
| Net Income | 21M | -73M | -135M |
| EPS | $0.37 | $-1.18 | $-2.20 |
| Free Cash Flow | 145M | 38M | -63M |
| ROIC | 21.7% | -32.6% | -75.5% |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | 0.97 | 0.69 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | 8.5M | -81M | -143M |
| Operating Margin | 4.7% | -107.3% | - |
| ROE | 8.5% | -36.2% | -75.5% |
| Shares Outstanding | 65M | 62M | 62M |
| Metric | |||
|---|---|---|---|
| Income Statement | |||
| Revenue | 0 | 76M | 182M |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -143M | -81M | 8.5M |
| Op. Margin | N/A | -107.3% | 4.7% |
| Net Income | -135M | -73M | 21M |
| Net Margin | N/A | -96.1% | 11.5% |
| Non-Recurring | 24K | 0 | 0 |
| Returns on Capital | |||
| ROIC | -75.5% | -32.6% | 21.7% |
| ROE | -75.5% | -36.2% | 8.5% |
| ROA | -44.6% | -19.6% | 4.6% |
| Cash Flow | |||
| Op. Cash Flow | -44M | 42M | 149M |
| Free Cash Flow | -63M | 38M | 145M |
| Owner Earnings | -67M | 16M | 123M |
| CapEx | 19M | 4.0M | 4.1M |
| Maint. CapEx | 6.2M | 8.1M | 8.1M |
| Growth CapEx | 13M | 0 | 0 |
| D&A | 6.2M | 8.1M | 8.1M |
| CapEx/OCF | N/A | 9.5% | 2.8% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 17M | 18M | 18M |
| Debt Repayment | 0 | 0 | 0 |
| Balance Sheet | |||
| Net Debt | N/A | N/A | -208M |
| Cash & Equiv. | N/A | N/A | 208M |
| Long-Term Debt | N/A | N/A | N/A |
| Debt/Equity | 0.69 | 0.97 | 0.00 |
| Interest Coverage | -15.4 | -7.7 | -7.7 |
| Equity | 179M | 223M | 246M |
| Total Assets | 304M | 439M | 460M |
| Total Liabilities | 125M | 216M | 214M |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | -366M | -439M | -439M |
| Working Capital | 190M | 220M | 220M |
| Current Assets | 236M | 377M | 377M |
| Current Liabilities | 47M | 157M | 157M |
| Per Share Data | |||
| EPS | -2.20 | -1.18 | 0.37 |
| Owner EPS | -1.08 | 0.26 | 1.89 |
| Book Value | 2.91 | 3.62 | 3.78 |
| Cash Flow/Share | -0.71 | 0.68 | 0.45 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 61.5M | 61.5M | 65.1M |
| Valuation | |||
| P/E Ratio | N/A | N/A | 48.0 |
| P/FCF | N/A | 11.4 | 7.9 |
| EV/EBIT | N/A | N/A | 109.8 |
| Price/Book | 2.0 | 1.9 | 4.6 |
| Price/Sales | N/A | 4.8 | 6.3 |
| FCF Yield | -17.2% | 8.8% | 12.7% |
| Market Cap | 365M | 434M | 1.1B |
| Avg. Price | 5.96 | 5.89 | 17.55 |
| Year-End Price | 5.93 | 7.06 | 17.55 |
Monte Rosa Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Monte Rosa Therapeutics, Inc. trades at 48.0x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 7.9x vs a median of 11.4x.
Monte Rosa Therapeutics, Inc. (GLUE) has a current P/E ratio of 48.0, compared to its historical median P/E of 15.0. The stock is currently considered Expensive based on its historical valuation range.
Monte Rosa Therapeutics, Inc. (GLUE) has a 5-year average return on invested capital (ROIC) of -54.1%. This is below average and may indicate limited pricing power.
Monte Rosa Therapeutics, Inc. (GLUE) has a market capitalization of $1.1B. It is classified as a small-cap stock.
Monte Rosa Therapeutics, Inc. (GLUE) does not currently pay a regular dividend.
Based on historical P/E analysis, Monte Rosa Therapeutics, Inc. (GLUE) appears expensive. The current P/E of 48.0 is 220% above its historical median of 15.0.
Monte Rosa Therapeutics, Inc. (GLUE) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Monte Rosa Therapeutics, Inc. (GLUE) reported annual revenue of $76 million in its most recent fiscal year, based on SEC EDGAR filings.
Monte Rosa Therapeutics, Inc. (GLUE) has a net profit margin of -96.1%. The company is currently unprofitable.
Monte Rosa Therapeutics, Inc. (GLUE) generated $38 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Monte Rosa Therapeutics, Inc. (GLUE) has a debt-to-equity ratio of 0.97. This indicates moderate leverage.
Monte Rosa Therapeutics, Inc. (GLUE) reported earnings per share (EPS) of $-1.18 in its most recent fiscal year.
Monte Rosa Therapeutics, Inc. (GLUE) has a return on equity (ROE) of -36.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 2 years of financial data for Monte Rosa Therapeutics, Inc. (GLUE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Monte Rosa Therapeutics, Inc. (GLUE) has a book value per share of $3.62, based on its most recent annual SEC filing.